ClinicalTrials.gg
CompletedNCT02513550IXORA-PUpdated Jun 17, 2020Results posted

A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis

A Phase 3 interventional study of Ixekizumab and Placebo in Plaque Psoriasis, sponsored by Eli Lilly and Company. Completed at 125 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-17.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,257
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.

Enrollment
3rd of 22
1,257 · median 156
Started
2015
with 2 others
Phase 3
11 of 22
none open now
Registered
8th of 22
by date
Lead sponsor
16 of 22
Eli Lilly and Company

Among the 22 studies testing ixekizumab in Psoriasis, this one is the 3rd largest by enrollment, is one of 3 that started in 2015, is one of 11 in phase 3, and was the 8th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ixekizumab

ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing ixekizumab in Psoriasis, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the efficacy of ixekizumab dosing regimens in participants with plaque psoriasis.

Read the detailed description

The purpose of this study is to evaluate both the safety and efficacy of ixekizumab dosing regimens. There are 3 study periods: Screening Period, Blinded Treatment Dosing Period, and Post-Treatment Follow-Up.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Present with chronic plaque psoriasis for at least 6 months prior to enrollment
  • At least 10% BSA of psoriasis at screening and at enrollment
  • sPGA score of at least 3 and PASI score of at least 12 at screening and at enrollment
  • Candidates for phototherapy and/or systemic therapy
  • Participant must agree to use reliable method of during the study; women must continue using birth control for at least 12 weeks after stopping treatment

Exclusion criteria

Exclusion Criteria:

  • Predominant pattern of pustular, erythrodermic, or guttate forms of psoriasis
  • History of drug-induced psoriasis
  • Cannot avoid excessive sun exposure or use of tanning booths for at least 4 weeks prior to enrollment and during the study
  • Received systemic non-biologic psoriasis therapy or phototherapy within the previous 4 weeks; or had topical psoriasis treatment within the previous 2 weeks prior to enrollment
  • Concurrent or recent use of any biologic agent
  • Have participated in any study with ixekizumab
  • Received a within 12 weeks prior to enrollment
  • Serious disorder or illness other than psoriasis
  • Ongoing or serious infection within the last 12 weeks or evidence of tuberculosis
  • Major surgery within 8 weeks of baseline, or will require surgery during the study
  • Breastfeeding or nursing (lactating) women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,257 participants (actual)

Study arms

  • Experimental
    80 mg Ixekizumab Q2W

    160 milligrams (mg) ixekizumab given as 2 subcutaneous (SQ) injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 2 weeks (Q2W) to week 52. Placebo administered SQ, Q2W to maintain blind.

    Drug: Ixekizumab · Drug: Placebo

  • Experimental
    80 mg Ixekizumab Q4W

    160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection every 4 weeks (Q4W) to week 52. Placebo administered SQ, Q2W to maintain blind.

    Drug: Ixekizumab · Drug: Placebo

  • Experimental
    80 mg Ixekizumab Q4W/Q2W

    160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.

    Drug: Ixekizumab · Drug: Placebo

  • Experimental
    80 mg Ixekizumab Q2W Maximum Extended Enrollment (ME2) Cohort

    160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q2W to week 52. Placebo administered SQ, Q2W to maintain blind.

    Drug: Ixekizumab · Drug: Placebo

  • Experimental
    80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort

    160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as 1 SQ injection Q4W to week 52. Placebo administered SQ, Q2W to maintain blind.

    Drug: Ixekizumab · Drug: Placebo

  • Experimental
    80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort

    160 mg ixekizumab given as 2 SQ injections at baseline and then 80 mg ixekizumab given as one SQ injection Q4W with step-up dosing to Q2W as needed (Q4W/Q2W step-up) to week 52. Placebo administered SQ, Q2W to maintain blind.

    Drug: Ixekizumab · Drug: Placebo

Interventions

  • Administered SQ

    Also known as: LY2439821

  • DrugPlacebo

    Administered SQ

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of (0,1)

    The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.

    Time frame: Week 52

  2. Percentage of Participants Achieving 75% Improvement in Psoriasis Area and Severity Index (PASI 75)

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants who did not meet the clinical response criteria or had missing data at Week52 were considered non-responders for NRI analysis.

    Time frame: Week 52

Secondary outcomes

  1. Percentage of Participants Achieving sPGA (0)

    The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.

    Time frame: Week 52

  2. Percentage of Participants Achieving PASI 90

    PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

    Time frame: Week 52

  3. Percentage of Participants Achieving PASI 100

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

    Time frame: Week 52

  4. Change From Baseline in PASI

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. Least Squares mean (LSmean) was calculated using Mixed-Effects Model of Repeated Measures (MMRM) analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

    Time frame: Baseline, Week 52

  5. Percent Improvement in PASI

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. Least Squares mean (LSmean) was calculated using Mixed-Effects Model of Repeated Measures (MMRM) analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

    Time frame: Baseline, Week 52

  6. Mean Change From Baseline in Percent Body Surface Area (BSA) Involvement

    The percentage involvement of psoriasis on each participant's body surface area (BSA) was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

    Time frame: Baseline, Week 52

  7. Mean Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score

    The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail (fn) Ps. This scale is used to evaluate the severity of fn bed Ps and fn matrix Ps by area of involvement in the fn unit. The fn is divided with imaginary horizontal and longitudinal lines into quadrants. Each fn is given a score for fn bed Ps (0 to 4) and fn matrix Ps (0 to 4) depending on presence (score of 1) or absence (score of 0) of any of the features of fn bed and fn matrix Ps in each quadrant. The NAPSI score of a fn is sum of scores in fn bed and fn matrix from each quadrant (maximum of 8). Each fn is evaluated, then the sum of all fn equals the total NAPSI score with a range from 0 to 80 (0 indicates no Ps, 80 indicates worst Ps). LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

    Time frame: Baseline, Week 52

  8. Mean Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score

    The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90-100%) with a total score ranging from 0 (less severity) to 72 (more severity). LS mean change was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

    Time frame: Baseline, Week 52

  9. Mean Change From Baseline in Palmoplantar PASI (PPASI)

    The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no PPASI) to 72 (most severe PPASI). The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

    Time frame: Baseline, Week 52

  10. Percentage of Participants Achieving an Itch Numeric Rating Scale (Itch NRS) ≥4 Point Reduction From Baseline

    The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours. Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.

    Time frame: Baseline, Week 52

  11. Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Total Score of 0 and 1 (DLQI [0,1])

    The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment). Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.

    Time frame: Week 52

  12. Change From Baseline in DLQI Total Score

    The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment). LS mean change was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

    Time frame: Baseline, Week 52

  13. Change From Baseline in Itch NRS Score

    The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours. LS mean change from baseline in PSSI was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

    Time frame: Baseline, Week 52

  14. Change From Baseline in Skin Pain Visual Analog Scale (VAS)

    The pain VAS is a participant-administered single-item scale designed to measure Skin pain from Psoriasis using a 0-100 millimeter (mm) horizontal VAS. Overall severity of participant's skin pain from Psoriasis is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no skin pain) to 100 mm (severe skin pain). LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

    Time frame: Baseline, Week 52

  15. Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) VAS

    EQ-5D-5L is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of 2 components: a descriptive system of the respondent's health and a rating of his/her current health state using a 0 (no pain) to 100mm VAS (severe pain). LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

    Time frame: Baseline, Week 52

  16. Pharmacokinetics (PK): Trough Concentration at Steady State (Ctrough,ss) of Ixekizumab

    Trough concentrations at steady state of Ixekizumab were evaluated.

    Time frame: Predose, Week 4, 12, 24, 36 and 52 Post dose

  17. Number of Participants With Anti-Ixekizumab Antibodies

    Number of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group.

    Time frame: Baseline through Week 52

07

Results

Posted Apr 18, 2018

Participant flow

Double Blind Treatment Period
Participant flow — Double Blind Treatment Period
Milestone80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort80 mg Ixekizumab Q2W Maximum Extended Enrollment Cohort
Started3103066119516
Received at least one dose of study drug3103066099516
Completed2742685379415
Not completed363874011
Withdrew: Withdrawal by subject111125000
Withdrew: Adverse event51317010
Withdrew: Lost to follow-up9711001
Withdrew: Lack of efficacy456000
Withdrew: Protocol violation114000
Withdrew: Physician decision204000
Withdrew: Site terminated by sponsor113000
Withdrew: Met exclusion criteria and was not dosed001000
Withdrew: Due to personal business201000
Withdrew: Death102000
Post-Treatment Follow-up Period
Participant flow — Post-Treatment Follow-up Period
Milestone80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort80 mg Ixekizumab Q2W Maximum Extended Enrollment Cohort
Started2852835599415
Completed2542444969415
Not completed313963000
Withdrew: Withdrawal by subject122026000
Withdrew: Early terminated but completed follow-up121620000
Withdrew: Lost to follow-up427000
Withdrew: Adverse event114000
Withdrew: Physician decision200000
Withdrew: Death001000
Withdrew: Subject move out of town001000
Withdrew: Subject did not come for visit-802003000
Withdrew: Labor reasons001000

Outcome measures

PrimaryPercentage of Participants Achieving Static Physician Global Assessment (sPGA) of (0,1)

The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of (0,1)
Percentage of participants80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W
Percentage of Participants Achieving Static Physician Global Assessment (sPGA) of (0,1)70.672.578.6
Statistical analysis
  • 80 mg Ixekizumab Q4W vs 80 mg Ixekizumab Q2W · Regression, Logistic · p = =0.005 · Risk difference (rd): 7.9
  • 80 mg Ixekizumab Q4W vs 80 mg Ixekizumab Q4W/Q2W · Regression, Logistic · p = =0.522 · Risk difference (rd): 1.9
PrimaryPercentage of Participants Achieving 75% Improvement in Psoriasis Area and Severity Index (PASI 75)

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants who did not meet the clinical response criteria or had missing data at Week52 were considered non-responders for NRI analysis.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving 75% Improvement in Psoriasis Area and Severity Index (PASI 75)
Percentage of participants80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W
Percentage of Participants Achieving 75% Improvement in Psoriasis Area and Severity Index (PASI 75)7983.785.9
Statistical analysis
  • 80 mg Ixekizumab Q4W vs 80 mg Ixekizumab Q2W · Regression, Logistic · p = =0.006 · Risk difference (rd): 6.9
  • 80 mg Ixekizumab Q4W vs 80 mg Ixekizumab Q4W/Q2W · Regression, Logistic · p = =0.118 · Risk difference (rd): 4.6
SecondaryPercentage of Participants Achieving sPGA (0)

The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving sPGA (0)
Percentage of participants80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W
Percentage of Participants Achieving sPGA (0)44.848.760.1
SecondaryPercentage of Participants Achieving PASI 90

PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving PASI 90
Percentage of participants80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W
Percentage of Participants Achieving PASI 9065.273.979.5
SecondaryPercentage of Participants Achieving PASI 100

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving PASI 100
Percentage of participants80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W
Percentage of Participants Achieving PASI 10043.549.359.7
SecondaryChange From Baseline in PASI

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. Least Squares mean (LSmean) was calculated using Mixed-Effects Model of Repeated Measures (MMRM) analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in PASI
units on a scale80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W
Change From Baseline in PASI-18.34 ± 0.22-18.95 ± 0.22-19.41 ± 0.17
SecondaryPercent Improvement in PASI

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region, yielding an overall score of 0 for no Ps to 72 for the most severe disease. Least Squares mean (LSmean) was calculated using Mixed-Effects Model of Repeated Measures (MMRM) analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percent change
Percent Improvement in PASI
Percent change80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W
Percent Improvement in PASI91.09 ± 0.8994.24 ± 0.9096.25 ± 0.71
SecondaryMean Change From Baseline in Percent Body Surface Area (BSA) Involvement

The percentage involvement of psoriasis on each participant's body surface area (BSA) was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Percent Body Surface Affected
Mean Change From Baseline in Percent Body Surface Area (BSA) Involvement
Percent Body Surface Affected80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W
Mean Change From Baseline in Percent Body Surface Area (BSA) Involvement-23.93 ± 0.34-24.62 ± 0.34-25.01 ± 0.27
SecondaryMean Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score

The NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail (fn) Ps. This scale is used to evaluate the severity of fn bed Ps and fn matrix Ps by area of involvement in the fn unit. The fn is divided with imaginary horizontal and longitudinal lines into quadrants. Each fn is given a score for fn bed Ps (0 to 4) and fn matrix Ps (0 to 4) depending on presence (score of 1) or absence (score of 0) of any of the features of fn bed and fn matrix Ps in each quadrant. The NAPSI score of a fn is sum of scores in fn bed and fn matrix from each quadrant (maximum of 8). Each fn is evaluated, then the sum of all fn equals the total NAPSI score with a range from 0 to 80 (0 indicates no Ps, 80 indicates worst Ps). LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score
units on a scale80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W
Mean Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score-19.27 ± 0.81-19.87 ± 0.83-20.82 ± 0.62
SecondaryMean Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score

The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90-100%) with a total score ranging from 0 (less severity) to 72 (more severity). LS mean change was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score
units on a scale80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W
Mean Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score-18.35 ± 0.31-18.73 ± 0.31-18.65 ± 0.24
SecondaryMean Change From Baseline in Palmoplantar PASI (PPASI)

The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no PPASI) to 72 (most severe PPASI). The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · units on a scale
Mean Change From Baseline in Palmoplantar PASI (PPASI)
units on a scale80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W
Mean Change From Baseline in Palmoplantar PASI (PPASI)-9.55 ± 0.31-9.37 ± 0.30-9.00 ± 0.26
SecondaryPercentage of Participants Achieving an Itch Numeric Rating Scale (Itch NRS) ≥4 Point Reduction From Baseline

The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours. Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.

Time frame:
Baseline, Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving an Itch Numeric Rating Scale (Itch NRS) ≥4 Point Reduction From Baseline
Percentage of participants80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W
Percentage of Participants Achieving an Itch Numeric Rating Scale (Itch NRS) ≥4 Point Reduction From Baseline74.072.377.2
SecondaryPercentage of Participants Achieving Dermatology Life Quality Index (DLQI) Total Score of 0 and 1 (DLQI [0,1])

The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment). Participants who did not meet the clinical response criteria or had missing data at Week 52 were considered non-responders for Non-Responder Imputation (NRI) analysis.

Time frame:
Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Total Score of 0 and 1 (DLQI [0,1])
Percentage of participants80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W
Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Total Score of 0 and 1 (DLQI [0,1])66.170.374.0
SecondaryChange From Baseline in DLQI Total Score

The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment). LS mean change was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in DLQI Total Score
units on a scale80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W
Change From Baseline in DLQI Total Score-9.70 ± 0.21-9.97 ± 0.22-10.23 ± 0.17
SecondaryChange From Baseline in Itch NRS Score

The Itch NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours. LS mean change from baseline in PSSI was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in Itch NRS Score
units on a scale80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W
Change From Baseline in Itch NRS Score-4.90 ± 0.13-5.15 ± 0.13-5.33 ± 0.10
SecondaryChange From Baseline in Skin Pain Visual Analog Scale (VAS)

The pain VAS is a participant-administered single-item scale designed to measure Skin pain from Psoriasis using a 0-100 millimeter (mm) horizontal VAS. Overall severity of participant's skin pain from Psoriasis is indicated by placing a single mark on the horizontal 100 mm scale from 0 mm (no skin pain) to 100 mm (severe skin pain). LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · mm
Change From Baseline in Skin Pain Visual Analog Scale (VAS)
mm80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W
Change From Baseline in Skin Pain Visual Analog Scale (VAS)-35.50 ± 0.94-36.77 ± 0.96-38.07 ± 0.74
SecondaryChange From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) VAS

EQ-5D-5L is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of 2 components: a descriptive system of the respondent's health and a rating of his/her current health state using a 0 (no pain) to 100mm VAS (severe pain). LS mean was calculated using MMRM analysis including dosing regimen, country, baseline weight category, baseline value, visit, dosing regimen-by-visit, and baseline value-by-visit interactions as fixed factors, with variance-covariance structure set to unstructured.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · mm
Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) VAS
mm80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W
Change From Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) VAS11.93 ± 0.9412.47 ± 0.9514.42 ± 0.74
SecondaryPharmacokinetics (PK): Trough Concentration at Steady State (Ctrough,ss) of Ixekizumab

Trough concentrations at steady state of Ixekizumab were evaluated.

Time frame:
Predose, Week 4, 12, 24, 36 and 52 Post dose
Reported as:
Geometric mean · microgram per milliliter (µg/mL)
Pharmacokinetics (PK): Trough Concentration at Steady State (Ctrough,ss) of Ixekizumab
microgram per milliliter (µg/mL)80 mg Ixekizumab Q4W Continuous80 mg Ixekizumab Q4W/Q2W No Step80 mg Ixekizumab Q4W/Q2W Step up80 mg Ixekizumab Q2W Continuous
Week 43.55 ± 764.03 ± 722.78 ± 677.87 ± 63
Week 122.72 ± 722.81 ± 801.95 ± 708.23 ± 56
Week 242.65 ± 732.71 ± 853.48 ± 787.89 ± 66
Week 362.83 ± 742.88 ± 735.76 ± 677.73 ± 76
Week 522.43 ± 792.77 ± 735.73 ± 686.96 ± 87
SecondaryNumber of Participants With Anti-Ixekizumab Antibodies

Number of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group.

Time frame:
Baseline through Week 52
Reported as:
Number · participants
Number of Participants With Anti-Ixekizumab Antibodies
participants80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W
Number of Participants With Anti-Ixekizumab Antibodies716484

Adverse events

Collected over Up to 19 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ixekizumab 80 mg Q4W - Treatment Period0/310 (0%)16/310 (5.2%)157/310 (50.6%)
80 mg Ixekizumab Q4W/Q2W - Treatment Period0/306 (0%)16/306 (5.2%)136/306 (44.4%)
80 mg Ixekizumab Q2W - Treatment Period0/609 (0%)32/609 (5.3%)285/609 (46.8%)
80 mg Ixekizumab Q4W - Post-Treatment Period0/285 (0%)1/285 (0.4%)16/285 (5.6%)
80 mg Ixekizumab Q4W/Q2W - Post-Treatment Period0/283 (0%)2/283 (0.7%)20/283 (7.1%)
80 mg Ixekizumab Q2W - Post-Treatment Period0/559 (0%)7/559 (1.3%)40/559 (7.2%)
80 mg Ixekizumab Q4W - Treatment Period ME2 Cohort0/9 (0%)0/9 (0%)6/9 (66.7%)
80 mg Ixekizumab Q4W/Q2W - Treatment Period ME2 Cohort0/5 (0%)1/5 (20%)4/5 (80%)
80 mg Ixekizumab Q2W - Treatment Period ME2 Cohort0/16 (0%)0/16 (0%)11/16 (68.8%)
80 mg Ixekizumab Q4W - Post-Treatment Period ME2 Cohort0/9 (0%)0/9 (0%)2/9 (22.2%)
80 mg Ixekizumab Q4W/Q2W - Post-Treatment Period ME2 Cohort0/4 (0%)0/4 (0%)0/4 (0%)
80 mg Ixekizumab Q2W - Post-Treatment Period ME2 Cohort0/15 (0%)0/15 (0%)2/15 (13.3%)
Most frequent serious events
Showing 10 of 87
Most frequent serious events
EventIxekizumab 80 mg Q4W - Treatment Period80 mg Ixekizumab Q4W/Q2W - Treatment Period80 mg Ixekizumab Q2W - Treatment Period80 mg Ixekizumab Q4W - Post-Treatment Period80 mg Ixekizumab Q4W/Q2W - Post-Treatment Period80 mg Ixekizumab Q2W - Post-Treatment Period80 mg Ixekizumab Q4W - Treatment Period ME2 Cohort80 mg Ixekizumab Q4W/Q2W - Treatment Period ME2 Cohort80 mg Ixekizumab Q2W - Treatment Period ME2 Cohort80 mg Ixekizumab Q4W - Post-Treatment Period ME2 Cohort80 mg Ixekizumab Q4W/Q2W - Post-Treatment Period ME2 Cohort80 mg Ixekizumab Q2W - Post-Treatment Period ME2 Cohort
Benign bone neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3100/3060/6090/2850/2830/5590/91/50/160/90/40/15
CellulitisInfections and infestations2/3102/3061/6090/2850/2830/5590/90/50/160/90/40/15
Rib fractureInjury, poisoning and procedural complications0/3102/3060/6090/2850/2831/5590/90/50/160/90/40/15
Ectopic pregnancyPregnancy, puerperium and perinatal conditions0/1110/1070/1990/980/981/1840/2—0/40/2—0/4
Tubal rupturePregnancy, puerperium and perinatal conditions0/1110/1070/1990/980/981/1840/2—0/40/2—0/4
Benign prostatic hyperplasiaReproductive system and breast disorders1/1990/1990/4100/1870/1850/3750/70/50/120/70/40/11
Breast cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3100/3060/6090/2851/2830/5590/90/50/160/90/40/15
Cerebrovascular accidentNervous system disorders0/3100/3061/6090/2851/2830/5590/90/50/160/90/40/15
Plasma cell myelomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3100/3060/6091/2850/2830/5590/90/50/160/90/40/15
Cardiac failureCardiac disorders0/3100/3062/6090/2850/2831/5590/90/50/160/90/40/15
Most frequent other events
Showing 10 of 47
Most frequent other events
EventIxekizumab 80 mg Q4W - Treatment Period80 mg Ixekizumab Q4W/Q2W - Treatment Period80 mg Ixekizumab Q2W - Treatment Period80 mg Ixekizumab Q4W - Post-Treatment Period80 mg Ixekizumab Q4W/Q2W - Post-Treatment Period80 mg Ixekizumab Q2W - Post-Treatment Period80 mg Ixekizumab Q4W - Treatment Period ME2 Cohort80 mg Ixekizumab Q4W/Q2W - Treatment Period ME2 Cohort80 mg Ixekizumab Q2W - Treatment Period ME2 Cohort80 mg Ixekizumab Q4W - Post-Treatment Period ME2 Cohort80 mg Ixekizumab Q4W/Q2W - Post-Treatment Period ME2 Cohort80 mg Ixekizumab Q2W - Post-Treatment Period ME2 Cohort
Viral upper respiratory tract infectionInfections and infestations41/31053/30673/6096/2850/2839/5591/91/56/160/90/40/15
Vaginal infectionInfections and infestations0/1111/1070/1990/980/980/1840/2—1/40/2—0/4
Upper respiratory tract infectionInfections and infestations46/31039/30669/6091/2853/2833/5592/91/51/160/90/40/15
MumpsInfections and infestations0/3100/3060/6090/2850/2830/5590/91/50/160/90/40/15
Blood glucose increasedInvestigations0/3100/3060/6090/2851/2830/5590/91/50/160/90/40/15
ArthralgiaMusculoskeletal and connective tissue disorders7/3105/30625/6092/2851/2834/5590/91/51/160/90/40/15
Benign bone neoplasmNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/3100/3060/6090/2850/2830/5590/91/50/160/90/40/15
RashSkin and subcutaneous tissue disorders3/3103/3064/6090/2850/2833/5590/91/50/160/90/40/15
Injection site erythemaGeneral disorders4/3103/30618/6090/2850/2830/5590/90/52/160/90/40/15
Injection site oedemaGeneral disorders1/3100/3061/6090/2850/2830/5590/90/52/160/90/40/15

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort80 mg Ixekizumab Q2W Maximum Extended Enrollment CohortTotal
Mean47.4 ± 13.5045.9 ± 12.8549.0 ± 13.6140.0 ± 9.6246.0 ± 13.1746.1 ± 13.0547.8 ± 13.45
Sex: Female, Male
Sex: Female, Male(Participants)80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort80 mg Ixekizumab Q2W Maximum Extended Enrollment CohortTotal
Female111107199204423
Male1991994127512834
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort80 mg Ixekizumab Q2W Maximum Extended Enrollment CohortTotal
Hispanic or Latino5955111000225
Not Hispanic or Latino24324448995161006
Unknown or Not Reported871100026
Race (NIH/OMB)
Race (NIH/OMB)(Participants)80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort80 mg Ixekizumab Q2W Maximum Extended Enrollment CohortTotal
American Indian or Alaska Native11122300046
Asian3132649516157
Native Hawaiian or Other Pacific Islander0040004
Black or African American1482200044
White251253486000990
More than one race311200016
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(Participants)80 mg Ixekizumab Q4W80 mg Ixekizumab Q4W/Q2W80 mg Ixekizumab Q2W80 mg Ixekizumab Q4W Maximum Extended Enrollment Cohort80 mg Ixekizumab Q4W/Q2W Maximum Extended Enrollment Cohort80 mg Ixekizumab Q2W Maximum Extended Enrollment CohortTotal
Puerto Rico14162900059
Argentina991900037
Romania55900019
Hungary11102300044
United States119118238000475
Czechia33800014
Japan52900016
Canada494999000197
South Korea111222951675
Taiwan56900020
Poland434383000169
Mexico1081700035
Australia14142800056
Germany12111800041
08

Study locations

125 sites
  • Total Skin and Beauty Dermatology Center PC
    Birmingham, Alabama 35205, United States
  • Anaheim Clinical Trials, LLC
    Anaheim, California 92801, United States
  • David Stoll, M.D.
    Beverly Hills, California 90212, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Center for Dermatology and Laser Surgery
    Sacramento, California 95819, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • University Clinical Trials, Inc.
    San Diego, California 92123, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Cherry Creek Research, Inc
    Denver, Colorado 80209, United States
  • Florida Academic Dermatology Centers
    Coral Gables, Florida 33134, United States
  • Avail Clinical Research LLC
    DeLand, Florida 32720, United States
  • Jacksonville Center for Clinical Research
    Jacksonville, Florida 32216, United States
  • Renstar Medical Research
    Ocala, Florida 34471, United States
  • Ameriderm Research
    Ormond Beach, Florida 32174, United States
  • University of South Florida
    Tampa, Florida 33624, United States
  • Advanced Medical Research
    Atlanta, Georgia 30342, United States
  • University Dermatology
    Darien, Illinois 60561, United States
  • Deaconess Clinic Inc
    Evansville, Indiana 47714, United States
  • Dawes Fretzin Clinical Research
    Indianapolis, Indiana 46256, United States
  • The South Bend Clinic
    South Bend, Indiana 46617, United States
  • Kansas City Dermatology, PA
    Overland Park, Kansas 66215, United States
  • Heartland Research Associates
    Wichita, Kansas 67207, United States
  • Dermatology Specialist
    Louisville, Kentucky 40202, United States
  • Dr. Shondra Smith MD
    Lake Charles, Louisiana 70605, United States
  • DermAssociates, P.C.
    Rockville, Maryland 20850, United States
  • ActivMed Practices & Research, Inc
    Beverly, Massachusetts 01915, United States
  • Central Dermatology PC
    Saint Louis, Missouri 63117, United States
  • ActivMed Practices & Research, Inc
    Newington, New Hampshire 03801, United States
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
  • Academic Dermatology Associates
    Albuquerque, New Mexico 87106-5239, United States
  • Mount Sinai School of Medicine Dermatology Clinical Trials
    New York, New York 10029, United States
  • Skin Search of Rochester, Inc
    Rochester, New York 14623, United States
  • University of North Carolina Dermatology and Skin Cancer Center
    Chapel Hill, North Carolina 27516, United States
  • PMG Research of Wilmington, LLC
    Wilmington, North Carolina 28401, United States
  • Wilmington Dermatology Center
    Wilmington, North Carolina 28405, United States
  • Piedmont Medical Research
    Winston-Salem, North Carolina 27103, United States
  • University Hospitals of Cleveland
    Cleveland, Ohio 44106-5055, United States
  • Healthcare Research Consultant
    Tulsa, Oklahoma 74135, United States
  • Oregon Dermatology and Research Center
    Portland, Oregon 97210, United States
  • Oregon Medical Research Center
    Portland, Oregon 97223, United States
  • Dermatology and Skin Surgery Center
    Exton, Pennsylvania 19341, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15213, United States
  • Pennsylvania Regional Center for Arthritis & Osteoarthritis
    Wyomissing, Pennsylvania 19610, United States
  • Yardley Dermatology
    Yardley, Pennsylvania 19067, United States
  • Clinical Partners LLC
    Johnston, Rhode Island 02919, United States
  • Coastal Carolina Research Center, Inc.
    Mount Pleasant, South Carolina 29464, United States
  • The Skin Wellness Center PC
    Knoxville, Tennessee 37922, United States
  • Austin Dermatology Associates
    Austin, Texas 78705, United States
  • Menter Dermatology Research Institute
    Dallas, Texas 75246, United States
  • Center for Clinical Studies
    Houston, Texas 77004, United States
  • Center for Clinical Studies
    Houston, Texas 77065, United States
  • Pflugerville Dermatology Clinical Research Center
    Pflugerville, Texas 78660, United States
  • Clinical Trials of Texas, Inc.
    San Antonio, Texas 78229, United States
  • Center for Clinical Studies
    Webster, Texas 77598, United States
  • University of Utah Medical Center
    Salt Lake City, Utah 84132, United States
  • Virginia Clinical Research
    Norfolk, Virginia 23507, United States
  • Dermatology Associates
    Seattle, Washington 98101, United States
  • Multicare Health System
    Tacoma, Washington 98405, United States
  • Wenatchee Valley Hospital & Clinics
    Wenatchee, Washington 98801, United States
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Buenos Aires, C1425DKG, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mendoza, 5500, Argentina
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Benowa, 4217, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Carlton, 3053, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Darlinghurst, 2010, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Fremantle, 6160, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Phillip, 02606, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Woolloongabba, 4102, Australia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Barrie, L4M 6L2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Calgary, T2G 1B1, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Halifax, B3H1Z2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Hamilton, L8N1V6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    London, N6A 3H7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Markham, L3P1X2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Montreal, H2K4L5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oakville, L6J7W5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Peterborough, K9J 5K2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Quebec, G1V 4X7, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Richmond Hill, L4B 1A5, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Sherbrooke, J1J 2G2, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Surrey, V3V 0C6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Waterloo, N2J 1C4, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Windsor, N8W 1E6, Canada
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Brno, 656 91, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Novy Jicin, 741 01, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Plzen-Bory, 305-99, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Praha, 100 34, Czechia
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Berlin, 10789, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Darmstadt, 64283, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Kiel, 24148, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Mahlow, 15831, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Munster, 48159, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Budapest, 1238, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Debrecen, 4032, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Oroshaza, 5901, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Szolnok, 5000, Hungary
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Osaka, 545-8586, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Takaoka, 9330871, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Tsu, 514-8507, Japan
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Bucheon, 420-717, Korea, Republic of
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Pusan, 602-739, Korea, Republic of

Showing the first 100 of 125 sites across 14 countries. Choose a country and city above to see the rest.

09

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2015, a primary completion of Nov 2016 and a completion of Aug 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2018, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2015
First posted
Jul 31, 2015
Start
Aug 2015
Primary completionActual
Nov 2016
CompletionActual
Aug 3, 2017
Results first posted
Apr 18, 2018
Last update
Jun 17, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 17, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02513550
Responsible party
Sponsor
First posted
Jul 31, 2015
Start date
Aug 2015
Primary completion
Nov 2016
Completion
Aug 3, 2017
Results posted
Apr 18, 2018
Last update
Jun 17, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion